**Abstract:** Primary focal segmental glomerulosclerosis (FSGS), along with minimal change disease (MCD), are diseases with primary damage to podocytes that are clinically manifested by the nephrotic syndrome. The pathogenesis of these podocytopathies is still unknown, and therefore, the search for biomarkers of these diseases is ongoing. Our aim was to determine the proteomic profile of urine from patients with FSGS and MCD. Patients with a confirmed diagnosis of FSGS (n = 30) and MCD (n = 9) were recruited for the study. For a comprehensive assessment of the severity of FSGS a special index was introduced, which was calculated as follows: the first score was assigned depending on the level of eGFR, the second score—depending on the proteinuria level, the third score—resistance to steroid therapy. Patients with the sum of these scores of less than 3 were included in group 1, with 3 or more—in group 2. The urinary proteome was analyzed using liquid chromatography/mass spectrometry. The proteome profiles of patients with severe progressive FSGS from group 2, mild FSGS from group 1 and MCD were compared. Results of the label free analysis were validated using targeted LC-MS based on multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS) available for 47 of the 76 proteins identified as differentiating between at least one pair of groups. Quantitative MRM SIS validation measurements for these 47 proteins revealed 22 proteins with significant differences between at least one of the two group pairs and 14 proteins were validated for both comparisons. In addition, all of the 22 proteins validated by MRM SIS analysis showed the same direction of change as at the discovery stage with label-free LC-MS analysis, i.e., up or down regulation in MCD and FSGS1 against FSGS2. Patients from the FSGS group 2 showed a significantly different profile from both FSGS group 1 and MCD. Among the 47 significantly differentiating proteins, the most significant were apolipoprotein A-IV, hemopexin, vitronectin, gelsolin, components of the complement system (C4b, factors B and I), retinol- and vitamin D-binding proteins. Patients with mild form of FSGS and MCD showed lower levels of Cystatin C, gelsolin and complement factor I.

**Keywords:** urine proteome; FSGS; MCD; podocyte dysfunction; mass spectrometry

---

1. **Introduction**

Primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) are diseases with primary damage to podocytes (primary podocytopathies), clinically manifested by high proteinuria and nephrotic syndrome [1,2]. FSGS is characterized...
by the presence of sclerosis in parts (segmental) of at least one glomerulus (focal) in a kidney biopsy specimen, when examined by light microscopy, immunofluorescence, or electron microscopy. Minimal change disease (MCD) is the leading cause of the nephrotic syndrome in children (approximately 90 percent) and in a minority of adults (approximately 10 percent) [3]. Light microscopy in case of MCD shows only a minor abnormality in the glomeruli, immunohistological methods display no deposits of immunoglobulins and complements, and electron microscopy reveals a diffuse loss of podocyte foot processes. Development of the nephrotic syndrome is due to the damage of the podocyte, foot process effacement and detachment of the podocyte from the glomerular basement membrane (GBM). As a result, proteins pass through the defects of the GBM and proteinuria develops. The onset of both diseases—FSGS and MCD, is usually acute with a severe nephrotic syndrome. A decrease in kidney function at the onset of the disease is diagnosed in 25–50% of patients, hematuria in 50%, and arterial hypertension in 20% of patients with FSGS [2,4].

Patients with MCD, as well as some patients with FSGS, respond well to steroid therapy [5]. However, 25–50% have steroid resistance—a severe form of FSGS. Severe FSGS is characterized by high proteinuria, renal impairment in the initial stages, and an unfavorable prognosis on the progression of renal dysfunction [2,4,6–8].

In primary FSGS, a putative circulating factor that is toxic to the podocyte causes generalized podocyte dysfunction. Secondary FSGS generally occurs as an adaptive phenomenon due to the reduction of the nephron mass or direct toxicity from drugs or viral infections. The circulating factor in FSGS and MCD is still unknown, and therefore the study of specific mechanisms that are involved in podocyte damage is ongoing. This knowledge could improve our understanding of the pathogenetic mechanisms of these diseases. Approaches based on mass spectrometry (MS) are the most objective and sensitive tools that have already provided most of the currently known information on the content of peptides and proteins in urine in various nephropathies [9–12]. The urinary proteome contains mainly (up to 70%) proteins and peptides of renal origin [13,14]. In general, this approach is the most appropriate for the search for potential biomarkers and mechanisms related to the development and progression of kidney diseases.

The aim of our study was to characterize changes in the urinary proteomic profiles of patients with different course of focal segmental glomerulosclerosis and minimal change disease to determine their specific biomarkers.

2. Results

2.1. Optimization of the Urine Preparation Protocol for Proteomic Analysis

All clinical urine samples were characterized by proteinuria of varying severity (Table 1). In order to select the optimal method of urine sample preparation for LC-MS/MS analysis 3 previously published methods for concentrating, purifying and hydrolyzing proteins were tested: (1) precipitation of proteins with ice-cold acetone [15]; (2) concentration and hydrolysis of proteins on filters (filter-aided sample preparation (FASP), Microcon (Millipore) filters were used) [16]; (3) ultrafiltration to purify proteins from low molecular weight components of urine [17]. The main criteria for the optimization of urine sample preparation were the robustness and ease of reproducibility of all steps; and the second the effectiveness of the protocol in the view of the number of detected proteins. It was decided not to use the third method due to its excessive laboriousness and poor reproducibility of the ultrafiltration stage for urine samples with proteinuria.
Table 1. Calculation of the FSGS severity index.

| Parameters                          | Score |
|-------------------------------------|-------|
| eGFR CKD-EPI, mL/min/1.73 m<sup>2</sup> |
| >60                                 | 0     |
| 45–59                               | 1     |
| 35–45                               | 2     |
| <35                                 | 3     |
| Proteinuria, g/24 h                 |
| >2                                  | 0     |
| 2–3                                 | 0.5   |
| 3–4                                 | 1     |
| 4–5                                 | 1.5   |
| 5–6                                 | 2     |
| 6–7                                 | 2.5   |
| >7                                  | 3     |
| Steroid resistance                  |
| Absent                              | 0     |
| Present                             | 1     |

Comparison of the two remaining methods of sample preparation showed that more different proteins was detected using the acetone precipitation method (Table 2, Figure 1). The first protocol allowed to detect the highest number of proteins in the test samples with proteinuria (5, 7, 10 mg/mL of total protein) and was used for further studies with minor modifications.

Table 2. Efficiency of urine proteins extraction by two methods (Acetone precipitation by ice-cold acetone protein precipitation; FASP—protein concentration and hydrolysis on filters). The number of identified proteins is indicated in Table.

| Method             | Sample 1 (5 mg/mL) | Sample 1 (7 mg/mL) | Sample 1 (10 mg/mL) |
|--------------------|--------------------|--------------------|--------------------|
| Acetone precipitation | 439               | 520                | 530                 |
| FASP               | 362               | 456                | 441                 |

Figure 1. Venn diagram comparing different methods of urine sample preparation for proteomic analysis (D—ice-cold acetone protein precipitation method; F—protein concentration and hydrolysis on filters (FASP)).

2.2. Label Free Analysis of the Urine Proteome for Patients with FSGS and MCD

Comparison of proteomic profiles of patients with FSGS and and MCD showed no significant differences in the protein levels (Figure 2).
Figure 2. Hierarchical clustering of proteins identified in urine samples of patients with MCD and FSGS. The box denotes log2-transformed values of peak intensity.

However, the FSGS group in total showed a high variability between the patients inside the group. Thus for a comprehensive assessment of this cohort, a special index was introduced, which was calculated as follows: the first score was assigned depending on the level of eGFR, the second—depending on the severity of proteinuria, the third—steroid resistance of the nephrotic syndrome. Steroid-resistance was defined as the absence of a decrease in proteinuria levels after 16 weeks of prednisolone therapy or a decrease by less than 50% of the baseline level.

The renal function was considered “saved”, if the estimated glomerular filtration rate, determined by the CKD-EPI formula (eGFR CKD-EPI), was above 60 mL/min/1.73 m²; and “impaired”—if it was less.

Using this index the patients with FSGS were subdivided into two groups: with a sum of scores of less than 3—mild FSGS (1), and with 3 or higher—severe progressive FSGS (2) (Table 1).

These two subgroups did not differ significantly in the severity of the nephrotic syndrome and renal dysfunction at the onset of the disease. However, in the follow-ups, the patients of the second group were characterized by a more severe FSGS course, meaning impaired renal function and steroid resistance. A wide range of urine proteins was detected at elevated levels in group 2 (Figure 3). For example, an increase in urinary excretion of complement components C3, C4B, factor B, as well as components of the membrane attack complex C8a and C9 were found. The detection of retinol-binding protein 4 and vitamin D-binding proteins in the urine is a consequence of tubulo-interstitial inflammation and injury of the tubular epithelium secondary to glomerular proteinuria [18–21]. Simultaneously with the interstitial inflammation, the accumulation of extracellular matrix (ECM) components and tubulo-interstitial fibrosis are also activated. Alpha-2-HS-glycoprotein can be attributed to the group of proteins responsible for active processes of ECM accumulation, expression of receptors on cells, and ECM protein metabolism (Figure 3).
Simultaneously with the interstitial inflammation, the accumulation of extracellular matrix (ECM) components and tubulointerstitial fibrosis are also activated. Alpha-2-HS-glycoprotein can be attributed to the group of proteins responsible for active processes of ECM accumulation, expression of receptors on cells, and ECM protein metabolism (Figure 3).

Figure 3. Hierarchical clustering of proteins identified in urine samples of patients with FSGS in group 1 and group 2. The box denotes log2-transformed values of peak intensity.

Considering patients with FSGS separately, we found some minor differences in the protein profiles of patients with saved and impaired renal function. In particular, patients with impaired renal function showed higher levels of thyroid hormone-binding protein, β2-microglobulin, vitamin D-binding protein, alpha-2-HS-glycoprotein (fetuin A) (Figure 4).

Proteins that differ between FSGS group 2 and MCD are by 83% identical to those differentiating the two FSGS groups (Figure 5). It can also be seen that like FSGS group 1 patients samples from MCD patients also have elevated levels of osteopontin and the inhibitor of phosphoinositide-3 kinase, while complement proteins, apolipoproteins, hemopexin, vitronectin, and other proteins in urine remain low (Figure 6).
Results of the label free analysis were validated using targeted LC-MS based on multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS) available for 47 of the 76 proteins identified as differentiating between at least one pair of groups (Supp. Table S1). Quantitative MRM SIS validation measurements for these 47 proteins revealed 22 proteins with significant differences between at least one of the two group pairs and 14 proteins were validated for both comparisons (Table 3). Also all of the 22 proteins validated by MRM SIS analysis showed the same direction of change as at the discovery stage with label-free LC-MS analysis, i.e., up or down regulation in MCD and FSGS1 against FSGS2. Moreover, it is worth to note that the absolute values of the measured proteins fold changes between groups for the two quantitation methods (label-free vs. MRM SIS) in their orders of magnitude are in good agreement (Supp. Table S1).
Figure 6. Hierarchical clustering of proteins identified in urine samples of patients with FSGS in group 2 and MCD. The color gradient denotes the log2-transformed ratio of the mean peak intensity values measured in the two groups.

The most important function and source of proteins are presented in Table 4. The levels of the most significant proteins in arbitrary units in FSGS group 1, FSGS group 2 and MCD are shown in Figures 7–9.
Table 3. Urinary proteins selected in this study for validation as perspective potential biomarkers for differentiating patients with MCD and FSGS (group 1—FSGS 1 and group 2—FSGS 2).

| Protein ID | Description                                           | FSGS 1 vs. FSGS 2 | FSGS 2 vs. MCD | Direction Change in FSGS 2 | Average Fold Change between Groups | Validated in at Least 1 Group | Validated in Both Groups |
|------------|-------------------------------------------------------|-------------------|----------------|-----------------------------|-----------------------------------|--------------------------------|-------------------------|
|            |                                                       | TIMS LFQ (Discovery Phase) | QQQ SIS MRM (Validation Phase) | TIMS LFQ (Discovery Phase) | QQQ SIS MRM (Validation Phase) |                              |                         |
| 1          | P04004  | Vitronectin                                         | +                  | +                  | +                  | +                  | up                      | 10                      | +                       | +                       |
| 2          | P06727  | Apolipoprotein A-IV                                 | +                  | +                  | +                  | +                  | up                      | 10                      | +                       | +                       |
| 3          | P19823  | Inter-alpha-trypsin inhibitor heavy chain H2         | +                  | +                  | +                  | +                  | up                      | 9                       | +                       | +                       |
| 4          | P02774  | Vitamin D-binding protein                           | +                  | +                  | +                  | +                  | up                      | 8                       | +                       | +                       |
| 5          | P61769  | Beta-2-microglobulin                                | +                  | +                  | +                  | +                  | up                      | 8                       | +                       | +                       |
| 6          | P0C0L5  | Complement C4-B                                     | +                  | +                  | +                  | +                  | up                      | 7                       | +                       | +                       |
| 7          | P02765  | Alpha-2-HS-glycoprotein                             | +                  | +                  | +                  | +                  | up                      | 6                       | +                       | +                       |
| 8          | P02790  | Hemopexin                                           | +                  | +                  | +                  | +                  | up                      | 6                       | +                       | +                       |
| 9          | P05155  | Plasma protease C1 inhibitor                         | +                  | +                  | +                  | +                  | up                      | 6                       | +                       | +                       |
| 10         | P02753  | Retinol-binding protein 4                           | +                  | +                  | +                  | +                  | up                      | 6                       | +                       | +                       |
| 11         | P00747  | Plasminogen                                          | +                  | +                  | +                  | +                  | up                      | 6                       | +                       | +                       |
| 12         | P00734  | Prothrombin                                          | +                  | +                  | +                  | +                  | up                      | 6                       | +                       | +                       |
| 13         | P02766  | Transthyretin                                        | +                  | +                  | +                  | +                  | up                      | 5                       | +                       | +                       |
| 14         | P06312  | Immunoglobulin kappa variable 4-1                   | +                  | +                  | +                  | +                  | up                      | 3                       | +                       | +                       |
| 15         | P10909  | Clustatin                                            | +                  | +                  | +                  | +                  | up                      | 3                       | +                       | +                       |
| 16         | P02748  | Complement component C9                             | +                  | +                  | +                  | +                  | up                      | 11                      | +                       | +                       |
| 17         | P00751  | Complement factor B                                  | +                  | +                  | +                  | +                  | up                      | 11                      | +                       | +                       |
| 18         | P51884  | Lumican                                              | +                  | +                  | +                  | +                  | up                      | 9                       | +                       | +                       |
Table 3. Cont.

| Protein ID | Description | TIMS LFQ (Discovery Phase) | QQQ SIS MRM (Validation Phase) | TIMS LFQ (Discovery Phase) | QQQ SIS MRM (Validation Phase) | Direction Change in FSGS 2 | Average Fold Change between Groups | Validated in at Least 1 Group | Validated in Both Groups |
|------------|-------------|----------------------------|--------------------------------|----------------------------|--------------------------------|-----------------------------|-------------------------------|-------------------------|-------------------------|
| 19 P05156  | Complement factor I | +                         | +                              | +                          | +                              | up                          | 6                            | +                       |
| 20 P01034  | Cystatin-C   | +                         | +                              | +                          | +                              | up                          | 3                            | +                       |
| 21 P06396  | Gelsolin     | +                         | +                              | +                          | +                              | up                          | 2                            | +                       |
| 22 Q08380  | Galectin-3-binding protein | +                        | +                              | +                          | +                              | down                        | 6                            | +                       |

Table 4. Description of urinary proteins selected in this study for differentiating patients with MCD and FSGS (group 1—FSGS 1 and group 2—FSGS 2).

| Protein Group | Description | Clinical/Histological Form | Pathogenetic Role |
|---------------|-------------|----------------------------|-------------------|
| 1             | Lumican     | FSGS 2 group               | Lumican, an extracellular matrix proteoglycan, related to ECM accumulation [22] |
| 2             | Vitamin D-binding protein | FSGS 2 group               | Potential marker of renal interstitial inflammation and fibrosis, and steroid-resistant nephrotic syndrome [18–20] |
| 3             | Plasminogen | FSGS 2 group               | Plasma abundant protein. Converts to plasmin, may activate epithelial sodium channels causing sodium retention and edema [23] |
| 4             | Hemopexin   | FSGS 2 group               | Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes [24–26] |
| 5             | Prothrombin | FSGS 2 group               | Plasma abundant protein |
| 6             | Complement factor I | FSGS 2 group               | Plasma abundant protein |
| 7             | Inter-alpha-trypsin inhibitor heavy chain H2 | FSGS 2 group               | The inter-alpha-trypsin inhibitors (ITI) are a family of structurally related plasma serine protease inhibitors involved in extracellular matrix stabilization. ITIs are involved in the accumulation of tubulo-interstitial fibrosis in severe forms of FSGS and it activates CD44 + parietal profibrogenic cells in FSGS [27–29] |
| 8             | Transthyretin | FSGS 2 group               | Plasma abundant protein |
### Table 4. Cont.

| Protein Group | Description | Clinical/Histological Form | Pathogenetic Role |
|---------------|-------------|-----------------------------|-------------------|
| 9             | Complement factor B | FSGS 2 group | The complement components C4B showed a massive increase in protein abundance in FSGS [30,31] |
| 10            | Apolipoprotein A-I | FSGS 2 group | ApoA-1b is noted to be present in the urine of recurrent FSGS possibly correlating with disease activity [32–34] |
|               | Apolipoprotein A-IV | FSGS 2 | Plasma abundant protein |
| 11            | Complement component C9 | FSGS 2 | The complement components C1 and C4B, properdin (CFP) showed a massive increase in protein abundance in FSGS [30], Activation of the C1 complex is under control of the C1-inhibitor. It forms a proteolytically inactive complex with the C1r or C1s proteases. May play a potentially crucial role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis and the generation of kinins. Acute phase marker [35] |
| 12            | Plasma protease C1 inhibitor | FSGS 2 | In proteinuric patients, significant urinary losses of fetuin-A may cause low serum fetuin-A levels. However, its peptides are elevated in the urine of patients with a high percentage of TIF [36,37] |
| 14            | Alpha-2-HS-glycoprotein/Fetuin A | FSGS 2 | It is filtered through the GBM and reabsorbed in the tubules, reflecting lysosomal proteolysis in the tubular epithelium. Its increase primarily indicates tubular damage. In addition, its level is associated with response to therapy. [21] |
| 15            | Retinol-binding protein 4 | FSGS 2 | Possibly vitronectin activation is involved in podocyte detachment from GBM [36] |
| 16            | Vitronectin | FSGS 2 | Vitronectin activates integrins, through which podocytes are attached to the GBM. | | | |
| 17            | Beta-2-microglobulin | FSGS 2 | Plasma abundant protein |
| 18            | Immunoglobulin kappa variable 4-1 | FSGS 2 | Plasma abundant protein |
| 19            | Gelsolin | FSGS 2 | Gelsolin, a Ca-dependent actin-binding protein, induces a change in the orientation of the actin filament, indicating a conformational change in actin [39,40] |
| 20            | Cystatin | FSGS 2 | Urinary cystatin C as a specific marker of tubular dysfunction [41] |
| 21            | Clusterin | FSGS 2 | Clusterin facilitates in vivo clearance of extracellular misfolded proteins and apoptosis. Clusterin has been postulated as a down modulator of the inflammatory response [42] |
| 22            | Complement C4-B | FSGS 2 | The complement components C1 and C4B, properdin (CFP) showed a massive increase in protein abundance in FSGS [30,43] |
| 23            | Galectin-3-binding protein | FSGS 1 and MCD | Galectin-3-binding protein is a secreted, hyperglycosylated protein expressed by the majority of human cells. Urinary G3BP is a non-invasive biomarker for clinically and histologically reflecting lupus nephritis activity [44,45] |
|               |             |               | total 22 proteins |
Figure 7. Protein levels in the urine of patients with FSGS (group 1—FSGS 1 and group 2—FSGS 2) and MCD in arb. units: (a) Vitronectin, (b) Apolipoprotein A-IV, (c) Hemopexin, (d) Inter-alfa-trypsin inhibitor heavy chain H2; (e) Vitamin-D-binding protein; (f) Retinol-binding protein.
Figure 8. Protein levels in the urine of patients with FSGS (group 1—FSGS 1 and group 2—FSGS 2) and MCD in arb. units: (a) beta-2 microglobulin, (b) Complement C4-b, (c) alfa-2-HS-glycoprotein, (d) Complement component C9; (e) Complement factor B; (f) Complement factor I.
**Figure 9.** Protein levels in the urine of patients with FSGS (group 1—FSGS 1 and group 2—FSGS 2) and MCD in arb. units: (a) lumican, (b) plasma protease C1 inhibitor, (c) galectin-3-binding protein.
3. Discussion

In the present study a wide variety of proteins was identified and quantitated using two mass-spectrometric approaches in urine samples of patients with FSGS and MCD. No significant differences were found between the proteomic profiles of patients with MCD and a general FSGS group. However, we found that the differences in the urinary protein profiles in FSGS patients were highly dependent on the severity of the disease—thus the patients were subdivided into those with mild FSGS—normal kidney function and steroid-sensitive NS, and those characterized by severe proteinuria, impaired renal function and steroid-resistant NS. These two groups showed significant differences in the levels of 68 proteins. The group with a severe progressive FSGS showed a number of abundant kidney-derived proteins in urine.

Apolipoproteins, vitronectin, hemopexin and gelsolin reflect the process of active damage to podocytes [24–26,32,34,38–40,46–51]. Apolipoprotein A-1 (ApoA-1), a small 28 kDa high-density lipoprotein (HDL) component, is considered as a putative permeability factor [32,34,50]. In a study by Puig-Gay N. et al. an increase in ApoA-1b in the urine was noted immediately before the onset of proteinuria in patients with FSGS recurrence in the transplant [32]. This protein is absent in the urine of healthy individuals and in most patients with glomerular proteinuria caused by other glomerulopathies [34,50]. Our data also suggests a potential role of ApoA in the pathogenesis of primary FSGS. In terms of response to therapy, our data is consistent with that of Kalantari et al. who differentiated steroid-sensitive and steroid-resistant patients with a confirmed FSGS by urine proteome analysis. Among 21 proteins, ApoA-1 was one of the most significant marker between steroid-sensitive and steroid-resistant forms. An increase in ApoA-1 is associated with hyperlipidemia and low-density lipoprotein oxidation [51].

Like Kalantari et al. and other groups of researchers, we established the role of ApoA-1 and some other urinary proteins in diagnosis of FSGS [32,51,52], however, we took a different approach in the study and introduced a specific index that allows us to evaluate not only the response to steroid therapy, but also and the level of proteinuria and kidney function. This approach has been more effective in separating FSGS patients by urinary proteome to two groups. In addition, the group of patients with mild FSGS is comparable to those with MCD, while the proteomic profile of the FSGS group 2 is significantly different, and apparently, this model can be used to assess the severity of the disease.

Among the biomarkers of podocyte damage, we found an increase in the level of hemopexin, which is a glycoprotein with the highest affinity for hem [24]. Hemopexin is currently considered as one of the possible circulating factors of idiopathic FSGS. Hemopexin binds free methemoglobin, further recognized by CD91 on hepatocytes or macrophages in the spleen, liver, and bone marrow [25]. Cell culture studies have shown that hemopexin can induce the redistribution of the actin cytoskeleton in podocytes and development of proteinuria [24–26].

An increase in the urinary excretion of vitronectin in FSGS patients is also of interest, since vitronectin activates β3-integrins, molecules that ensure the fixation of podocytes to the GBM. In case of FSGS, the loss of vitronectin may be associated with the process of podocyte detachment from the glomerular basement membrane [38]. Elevated serum gelsolin aggravates the development of proteinuria and renal dysfunction by F-actin rearrangement, foot process effacement and cell movement [39,40]. These markers of podocyte dysfunction were elevated only in severe steroid-resistant FSGS.

In group 1, patients with mild FSGS, other factors of podocyte dysfunction are detected in the urine—galectin-3—binding protein. It is suggested that this protein is elevated in the kidney tissue in MCD and in the urine in lupus nephritis, and it appears to have a pro-inflammatory function [44,45].

Compared to other glomerulopathies, complement activation processes are not well understood in FSGS. In the second FSGS group we found a significant increase in urinary excretion of complement components C4b, C9, as well as factor B, I and a decrease in CD59, an inhibitor of the membrane attack complex, which indicates the possible role of
complement activation associated with stronger damage. Our data is consistent with the results of a study by Huang J. et al., who showed the possibility of systemic complement activation in FSGS patients with increased levels of C3a, C5a, and C5b-9 in blood plasma and urine [43]. Activation of the alternative complement pathway in FSGS may be associated with a poor prognosis [30,31]. On the other hand, an increase in the level of some complement components in the urine may be the result of loss due to severe glomerular filter damage. For a more accurate assessment of complement system disorders in FSGS, the study these components in the blood of these patients is required.

The intensity of accumulation of ECM components is reflected by the excretion of fetuin A, β2 microglobulin, and immunoglobulin chains in the urine of patients with FSGS [37]. The same changes in the protein profiles indicating the damaging processes on tubular cells and accumulation of ECM in the interstitium can be noticed in patients with FSGS with impaired renal function resistant to steroid therapy in our study. An equally important component of disease progression and lack of response to steroid therapy is tubulointerstitial fibrosis and tubular damage in FSGS, which are reflected by an increase in the level in the urine of lumican and cystatin C. These processes are also evidenced by an increase in vitamin D-binding protein and retinol-binding protein 4 in the urine of FSGS patients with impaired renal function [18–21,37]. Simultaneously with the processes of interstitial inflammation, the mechanisms of accumulation of ECM components are activated [18–20]. Our data confirms the results of experimental studies [23,27–29,52]. A study of urinary proteins dynamic changes was conducted on a focal segmental glomerulosclerosis rat model (adriamycin-induced nephropathy) and showed that levels of Fetuin-A and alpha 1 microglobulin may be promising markers for early detection of FSGS. Thus, some proteins or their combinations can change with the disease progression [52]. Inter-alpha-trypsin inhibitor heavy chain H1 and H2 activate the CD44+ parietal epithelial cells, the main profibrogenic cells in the glomeruli, and thus are a powerful stimulus for glomerulosclerotic processes [27–29].

Many urine proteins are of serum origin and enter the urine through the damaged glomerular filter. However, these proteins can cause additional damage and pathology progression. For example, components of the complement system or plasminogen. The conversion of plasminogen to plasmin in urine can activate the epithelial sodium channels and cause sodium retention in the renal tubules—one of the mechanisms of renal edema [23]. Interestingly, in case of MCD and mild FSGS with a favorable prognosis, some of the proteins found in the urine seem to be of a protective nature, such as for example plasma protease C1 [35].

Perez et al. analyzed urinary peptide profiles using magnetic bead-based technology, combined with MALDI-TOF mass spectrometry, in 44 patients diagnosed with MCD and FSGS. In this work the low molecular weight fraction of urine, containing peptides of proteins were analyzed, while in our work the high-molecular protein fraction was isolated. The authors showed that FSGS patients had higher levels of uromodulin fragments and lower concentrations of fragments of A1AT [53]. In 2017 Perez V. et al. also ran a study that included 24 patients with MCD and 25 patients with FSGS and analyzed their urine proteome using two-dimensional gel electrophoresis in combination with MS to detect urinary biomarkers capable of differentiating MCD and FSGS. They showed that urine concentrations of alpha-1 antitrypsin, transferrin, histatin-3, and 39S ribosomal protein L17 were decreased in the FSGS group, and the calretinin level was increased as compared to the MCD group [54]. We did not find any significant differences between the MCD and the general FSGS groups. However, we found an increase in alpha-1 antitrypsin, and other proteins in patients with severe FSGS as compared with those with MCD and mild FSGS, who showed similar profiles of urine proteins.

Thus, we have identified a wide range of proteins that differ in patients with mild course of steroid-sensitive FSGS/MCD and FSGS patients with a progressive steroid-resistant NS. Proteins excreted in the urine reflect damage to several parts of the nephron—podocytes, tubulo-interstitium, accumulation of ECM, complement activation. Patients
with MCD and FSGS with steroid-sensitivity and a favorable course of progress showed similar urine protein profiles, while severe progressive FSGS with steroid-resistant nephrotic syndrome were characterized by the early activation of the complement system and profibrogenic mechanisms and accumulation of extracellular matrix components at the onset of the disease.

4. Materials and Methods

4.1. Clinical Characteristics of the Patients

Patients with a confirmed diagnosis of FSGS (n = 30) and MCD (n = 9) were recruited for the study, 20 men and 19 women, aged 19 to 69 years, median 37 years [27,57]. The exclusion criteria were: active urinary infection, diabetes mellitus, obesity, severe arterial hypertension, liver disease, rheumatic systemic diseases, stage 5 chronic kidney disease. Impaired renal function (eGFR CKD-EPI < 60 mL/min/1.73 m²) was detected in 16 patients, saved kidney function—in 23 (eGFR CKD-EPI > 60 mL/min/1.73 m²).

The characteristics of the examined patients are presented in Table 5.

Table 5. Characteristics of the patients.

| Parameters               | FSGS 1 (n = 30) | MCD 2 (n = 9) |
|--------------------------|-----------------|---------------|
| Age, years               | 40 (27.3; 57.8) | 35 (28; 59)   |
| Gender (male), n (%)     | 18 (60)         | 2 (22.2)      |
| Arterial hypertension, n (%) | 22 (73.3)     | 2 (22.2)      |
| Proteinuria, g/24h       | 3.66 (2.50; 5.00) | 3.24 (2.03; 5.5) |
| Serum albumin, g/L       | 26.55 (20.85; 33.68) | 29.3 (20.00; 35.80) |
| Serum protein, g/L       | 50.8 (40.86; 58.23) | 61.4 (46.5; 65.3) |
| Nephrotic syndrome, n (%)| 21 (70)         | 9 (100)       |
| Creatinine, mkmol/L      | 109.31 (77.57; 152.65) | 85.9 (71.8; 115.9) |
| eGFR CKD-EPI, mL/min/1.73 m² | 64.68 (41.4; 97.09) | 73 (55.58; 105.00) |
| eGFR< 60 mL/min/1.73 m², n (%) | 12 (40.0) | 4 (44.4) |
| Steroid-resistant NS, n (%) | 14 (46.7)  | 0             |

1 Focal segmental glomerulosclerosis, 2 Minimal change disease, 3 Estimated glomerular filtration rate using the CKD-EPI formula. The table shows the median, in brackets—the 1st and 3rd quartiles.

4.2. Urine Sample Preparation for LC-MS/MS

First morning urine samples were collected from all examined patients. The middle portion of freshly passed morning urine was collected in 10 mL test tubes, centrifuged at 3000 rpm for 15 min, the supernatant was frozen in 1 mL aliquots and stored at −20 °C.

Urine aliquots with a volume of 0.1 mL were quickly thawed and 0.5 mL of cold acetone was added to precipitate proteins overnight at −20 °C. Then the samples were centrifuged at 20,000 × g for 10 min, the supernatant was removed, the precipitate was dissolved in 50 µL of 8 M urea/200 mM Tris-HCL, pH 8.5. The proteins were restored with 5 mM dithiotreitol for 30 min at 37 °C, alkylated with 20 mM iodoacetamide in the dark for 30 min. Before hydrolysis, 200 µL of deionized water was diluted, trypsin (Trypsin Gold, Promega, Madison, WI, USA) was added in an enzyme-protein ratio of 1:25, incubated overnight at 37 °C. The reaction was stopped by adding formic acid to the final concentration of 1%. Peptides were centrifuged at 18,000 × g, the supernatant was left for desalting. Desalting was carried out by solid-phase extraction using plates (Oasis HLB 96-well Microelution Plate, Waters, Beverley, MA, USA). The eluate was lyophilized and dissolved in 0.1% formic acid to a concentration of 0.5mg/mL for further LC-MS/MS analysis.

4.3. Label-Free Untargeted LC-MS/MS Urine Proteomic Analysis

The resulting tryptic peptide mixture was analyzed using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method based on a nano-HPLC Dionex Ultimate3000 system (Thermo Fisher Scientific, Madison, WI, USA) and a timsTOF Pro (Bruker Daltonics, Billerica, MA, USA) mass spectrometer. A packed emitter column (C18, 25 cm × 75 μm 1.6 μm) (Ion Optics, Parkville, Australia) was used to separate peptides.
at a flow rate of 400 nL/min by gradient elution from 4% to 90% of phase B during 40 min. Mobile phase A consisted of 0.1% formic acid in water and mobile phase B consisted of 0.1% formic acid in acetonitrile.

Mass spectrometric analysis was performed using the parallel accumulation serial fragmentation (PASEF) acquisition method. An electrospray ionization (ESI) source was operated at 1500 V capillary voltage, 500 V end plate offset and 3.0 L/min of dry gas at temperature of 180 °C. The measurements were carried out in the m/z range from 100 to 1700 Th. The ion mobility was in the range from 0.60 to 1.60 V s/cm². The total cycle time was 1.88 s and the number of PASEF MS/MS scans was set to 10.

Targeted quantitative LC-MS/MS using multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS).

Targeted quantitative LC-MS analysis was carried out using synthetic stable-isotope labeled internal standard (SIS) and natural (NAT) synthetic proteotypic peptides for measurements of the corresponding proteins in urine. The selected 22 SIS and NAT synthetic peptides had been previously validated for use in LC/MRM-MS experiments [55]. LC-MS parameters, such as the LC gradient and the MRM parameters (Q1 and MRM scans) were adapted and optimized based on the previous studies [56]. The SIS peptide mixture was spiked in each urine sample at a balanced concentration which was optimized in experiments with dilution series of urine samples with proteinuria. Standard curves were generated using NAT and SIS peptide standards with a pooled urine sample as matrix.

All samples were analyzed in duplicate by HPLC-MS system consisting of an Ex-ionLC™ (UHPLC system (ThermoFisher Scientific, Waltham, MA, USA) coupled online to a SCIEX QTRAP 6500+ triple quadrupole mass spectrometer (SCIEX, Toronto, ON, Canada). The loaded sample volume was 10 µL per injection. HPLC separation was carried out using Zorbax Eclipse Plus C18 RRHD column (150 × 2.1 mm, 1.8 µm) (Agilent, Santa Clara, CA, USA) with gradient elution. Mobile phase A was 0.1% FA in water; mobile phase B was 0.1% FA in acetonitrile. LC separation was performed at a flow rate of 0.4 mL/min using a 53 min gradient from 2 to 45% of mobile phase B. Mass-spectrometric measurements were carried out using the MRM acquisition method. The electrospray ionization (ESI) source settings were as follows: ion spray voltage 4000 V, temperature 450 °C, ion source gas 40 L/min. The corresponding transition list for MRM experiments with retention times values and Q1/Q3 masses for each peptide were adapted from the previous studies [56].

Skyline Quantitative Analysis software (version 20.2.0.343, University of Washington) was used for quantitative analysis.

4.4. Data Analysis

The data obtained were analyzed using PEAKS XPro software (BSI, North Waterloo, ON, Canada) according to the following parameters: parent mass error tolerance −20 ppm; fragment mass error tolerance 0.03 Da; enzyme—trypsin; missed cleavages—3; fixed modifications—Carbamidomethyl (C); variable modifications—Oxidation (M), Acetylation (N-term). The search was carried out using the SwissProt Human database. False discovery rate threshold was set to 0.01. Scripts written in R version 3.3.3 [58] and RStudio 1.383 [57] were used for statistical processing of the results.

5. Conclusions

Thus, the proteomic profile of urine from patients with FSGS and MCD is characterized by a large number of excreted proteins, but no significant differences between these two forms were revealed. However, the FSGS patients showed high variability inside the group and clustered into two subgroups, which could be reliably distinguished basing on the proteomic profile. Results of the label free analysis were validated using targeted LC-MS based on multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS) available for 47 of the 76 proteins identified as differentiating between at least one pair of groups. Quantitative MRM SIS validation measurements for these 47 proteins revealed 22 proteins with significant differences between at least one of the
two group pairs and 14 proteins were validated for both comparisons. In addition, all of the 22 proteins validated by MRM SIS analysis showed the same direction of change as at the discovery stage with label-free LC-MS analysis, i.e., up or down regulation in MCD and FSGS1 against FSGS2. In patients with severe FSGS, the urine proteome panel reflects damage to podocytes (Vitronectin, Hemopexin, Gelsolin, Apolipoprotein A), complement activation (Complement component C4b, C9, Complement factor B and I), and accumulation of the extracellular matrix and tubular damage (Cystatin C, Vitamin D-binding protein, Retinol-binding protein 4, Alpha-2-HS-glycoprotein, Plasma protease C1 inhibitor, Lumican, Clusterin).

**Supplementary Materials:** The following supporting information can be downloaded at: [https://www.mdpi.com/article/10.3390/ijms232012607/s1](https://www.mdpi.com/article/10.3390/ijms232012607/s1).

**Author Contributions:** Conceptualization, N.V.C. and A.S.K.; methodology, D.N.K.; software, A.G.B.; formal analysis, A.G.B. and D.N.K.; investigation, A.V., A.E.B., M.I.I. and N.V.C.; data curation, M.L. and S.M.; writing—original draft preparation, N.V.C. and A.S.K.; writing—review and editing, E.N.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Russian Science Foundation, grant #21-74-20173.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by Ethical Committee of the Medical Research and Educational Center of Lomonosov University, Approval Code: Protocol 12/21, Approval Date: 13 December 2021.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| A1AT         | Alpha-1 antitrypsin |
| ApoA-1       | Apolipoprotein A-1 |
| CD2AP        | CD2 Associated Protein |
| CFP          | Complement factor P (properdin) |
| CKD-EPI      | Chronic Kidney Disease Epidemiology Collaboration formula |
| ECM          | Extracellular matrix |
| ESI          | Electrospray ionization |
| eGFR         | Estimated glomerular filtration rate |
| FASP         | Filter-aided sample preparation |
| FSGS         | Focal segmental glomerulosclerosis |
| GBM          | Glomerular basement membrane |
| HDL          | High-density lipoprotein |
| HPLC         | High-performance liquid chromatography |
| LC-MS        | Liquid chromatography—mass spectrometry |
| LC-MS/MS     | Liquid chromatography with tandem mass spectrometry |
| LC/MRM-MS    | Liquid chromatography/Multiple reaction monitoring—mass spectrometry |
| LDL          | Low density lipoproteins |
| MALDI-TOF MS | Matrix-Assisted Laser Desorption—Ionisation-Time of Flight Mass Spectrometry |
| MCD          | Minimal change disease |
| MRM          | Multiple reaction monitoring |
| MS           | Mass spectrometry |
| NAT          | Natural synthetic proteotypic peptides |
| NS           | Nephrotic syndrome |
| PASEF        | Parallel Accumulation—Serial Fragmentation method |
| PEDF         | Pigment epithelium-derived factor |
| SIS          | Stable isotope labelled peptide standards |
| TIF          | Tubulointerstitial fibrosis |
References

1. Praga, M.; Morales, E.; Herrera, J.C.; Campos, A.P.; Domínguez-Gil, B.; Alegre, R.; Vara, J.; Martínez, M.A. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. *Am. J. Kidney Dis. 1999*, **33**, 52–58. [CrossRef]

2. Rydel, J.J.; Korbet, S.M.; Borok, R.Z.; Schwartz, M.M. Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. *Am. J. Kidney Dis. 1995*, **25**, 534–542. [CrossRef]

3. Vivarelli, M.; Massella, L.; Ruggiero, B.; Emma, F. Minimal Change Disease. *Clin. J. Am. Soc. Nephrol. 2016*, **12**, 332–345. [CrossRef][PubMed]

4. Chun, M.J.; Korbet, S.M.; Schwartz, M.M.; Lewis, E.J. Focal Segmental Glomerulosclerosis in Nephrotic Adults: Presentation, Prognosis, and Response to Therapy of the Histologic Variants. *J. Am. Soc. Nephrol. 2004*, **15**, 2169–2177. [CrossRef]

5. Nakayama, M.; Katafuchi, R.; Yanase, T.; Ikeda, K.; Tanaka, H.; Fujimi, S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. *Am. J. Kidney Dis. 2002*, **39**, 503–512. [CrossRef]

6. Korbet, S.M.; Schwartz, M.M.; Lewis, E.J. Primary Focal Segmental Glomerulosclerosis: Clinical Course and Response to Therapy. *Am. J. Kidney Dis. 1994*, **23**, 773–783. [CrossRef]

7. Wehrmann, M.; Bohle, A.; Held, H.; Schumm, G.; Kendziorra, H.; Pressler, H. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. *Clin. Nephrol. 1990*, **33**, 115–122.

8. Sethi, S.; Zand, L.; Nasr, S.H.; Glassock, R.J.; Fervenza, F.C. Focal and segmental glomerulosclerosis: Clinical and kidney biopsy correlations. *Clin. Kidney J. 2014*, **7**, 531–537. [CrossRef]

9. Cunningham, R.; Ma, D.; Li, L. Mass spectrometry-based proteomics and peptidomics for systems biology and biomarker discovery. *Front. Biol. 2012*, **7**, 313–335. [CrossRef]

10. Di Meo, A.; Pasic, M.D.; Yousef, G.M. Proteomics and peptidomics: Moving toward precision medicine in urological malignancies. *Oncotarget 2016*, **7**, 52460–52474. [CrossRef]

11. Feist, P.; Hummon, A.B. Proteomic Challenges: Sample Preparation Techniques for Microgram-Quantity Protein Analysis from Biological Samples. *Int. J. Mol. Sci. 2015*, **16**, 3537–3563. [CrossRef]

12. Filip, S.; Pontillo, C.; Schanstra, J.P.; Vlahou, A.; Mischak, H.; Klein, J. Urinary proteomics and molecular determinants of chronic kidney disease: Possible link to proteases. *Expert Rev. Proteom. 2014*, **11**, 535–548. [CrossRef]

13. Mischak, H.; Delles, C.; Vlahou, A.; Vanholder, R. Proteomic biomarkers in kidney disease: Issues in development and implementation. *Nat. Rev. Nephrol. 2015*, **11**, 221–232. [CrossRef]

14. Decramer, S.; de Peredo, A.G.; Breuil, B.; Mischak, H.; Monsarrat, B.; Bascands, J.-L.; Schanstra, J.P. Urine in Clinical Proteomics. *Mol. Cell. Proteom. 2008*, **7**, 1850–1862. [CrossRef][PubMed]

15. Ding, H.; Fazelinia, H.; Spruce, L.A.; Weiss, D.A.; Zderic, S.A.; Seeholzer, S.H. Urine Proteomics: Evaluation of Different Sample Preparation Workflows for Quantitative, Reproducible, and Improved Depth of Analysis. *J. Proteome Res. 2020*, **19**, 1857–1862. [CrossRef][PubMed]

16. Wiśniewski, J. Filter-Aided Sample Preparation: The Versatile and Efficient Method for Proteomic Analysis. *Methods Enzym. 2017*, **585**, 15–27. [CrossRef]

17. Percy, A.J.; Yang, J.; Hardie, D.B.; Chambers, A.G.; Tamura-Wellis, J.; Borchers, C.H. Precise quantitation of 136 urinary proteins by LC/MS-MS using stable isotope labeled peptides as internal standards for biomarker discovery and/or verification studies. *Methods 2015*, **81**, 24–33. [CrossRef][PubMed]

18. Bennett, M.R.; Pordal, A.; Haffner, C.; Pleasent, L.; Ma, Q.; Devajaran, P. Urinary Vitamin D-Binding Protein as a Biomarker of Steroid-Resistant Nephrotic Syndrome. *Biomark. Insights 2016*, **11**, 1–6. [CrossRef]

19. Mirković, K.; Doorenbos, C.R.C.; Dam, W.A.; Heerspink, H.J.L.; Slagman, M.C.J.; Nauta, F.L.; Kramer, A.B.; Gansevoort, R.T.; Born, J.V.D.; Navis, G.; et al. Urinary Vitamin D Binding Protein: A Potential Novel Marker of Renal Interstitial Inflammation and Fibrosis. *PLoS ONE 2013*, **8**, e55887. [CrossRef]

20. Choudhary, A.; Mohanraj, P.S.; Krishnamurthy, S.; Rajappa, M. Association of Urinary Vitamin D Binding Protein and Neutrophil Gelatinase-Associated Lipocalin with Steroid Responsiveness in Idiopathic Nephrotic Syndrome of Childhood. *Saudi J. Kidney Dis. Transpl. 2020*, **31**, 946–956. [CrossRef]

21. Kirsztajn, G.M.; Nishida, S.K.; Silva, M.S.; Ajzen, H.; Pereira, A.B. Urinary retinol-binding protein as a prognostic marker in the treatment of nephrotic syndrome. *Nephron Exp. Nephrol. 2000*, **86**, 109–114. [CrossRef]

22. Feng, S.; Gao, Y.; Yin, D.; Lv, L.; Wen, Y.; Li, Z.; Wang, B.; Wu, M.; Liu, B. Identification of Lumican and Fibromodulin as Hub Genes Associated with Accumulation of Extracellular Matrix in Diabetic Nephropathy. *Kidney Blood Press Res. 2021*, **46**, 275–285. [CrossRef]

23. Svenningsen, P.; Bistrup, C.; Friis, U.G.; Bertog, M.; Haerteteis, S.; Krueger, B.; Stubbe, J.; Jensen, O.N.; Thiessen, H.C.; Uhrenholt, T.R.; et al. Plasmin in Nephrotic Urine Activates the Epithelial Sodium Channel. *J. Am. Soc. Nephrol. 2008*, **20**, 299–310. [CrossRef]

24. Lennon, R.; Singh, A.; Welsh, G.I.; Coward, R.J.; Satchell, S.; Ni, L.; Mathieson, P.W.; Bakker, W.W.; Saleem, M.A. Hemopexin Induces Nephrin-Dependent Reorganization of the Actin Cytoskeleton in Podocytes. *J. Am. Soc. Nephrol. 2008*, **19**, 2140–2149. [CrossRef]

25. Pukaljo-Marczyk, A.; Zwoliriska, D. Involvement of Hemopexin in the Pathogenesis of Proteinuria in Children with Idiopathic Nephrotic Syndrome. *J. Clin. Med. 2021*, **10**, 3160. [CrossRef]
51. Kalantari, S.; Nafar, M.; Rutishauser, D.; Samavat, S.; Rezaei-Tavirani, M.; Yang, H.; Zubarev, R.A. Predictive urinary biomarkers for steroid-resistant and steroid-sensitive focal segmental glomerulosclerosis using high resolution mass spectrometry and multivariate statistical analysis. *BMC Nephrol.* 2014, 15, 141. [CrossRef]
52. Zhao, M.; Li, M.; Li, X.; Shao, C.; Yin, J.; Gao, Y. Dynamic changes of urinary proteins in a focal segmental glomerulosclerosis rat model. *Proteome Sci.* 2014, 12, 42. [CrossRef]
53. Pérez, V.; Ibernón, M.; López, D.; Pastor, M.C.; Navarro, M.; Navarro-Muñoz, M.; Bonet, J.; Romero, R. Urinary Peptide Profiling to Differentiate between Minimal Change Disease and Focal Segmental Glomerulosclerosis. *PLoS ONE* 2014, 9, e87731. [CrossRef]
54. Pérez, V.; López, D.; Boixadera, E.; Ibernón, M.; Espinal, A.; Bonet, J.; Romero, R. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis. *BMC Nephrol.* 2017, 18, 49. [CrossRef]
55. Kuzyk, M.A.; Parker, C.E.; Domanski, D.; Borchers, C.H. Development of MRM-based assays for the absolute quantitation of plasma proteins. *Methods Mol. Biol.* 2013, 1023, 53–82. [CrossRef]
56. Kononikhin, A.S.; Zakharova, N.V.; Semenov, S.D.; Bugrova, A.E.; Brzhozovskiy, A.G.; Indeykina, M.I.; Fedorova, Y.B.; Kolykhalov, I.V.; Strelnikova, P.A.; Ikonnikova, A.Y.; et al. Prognosis of Alzheimer’s Disease Using Quantitative Mass Spectrometry of Human Blood Plasma Proteins and Machine Learning. *Int. J. Mol. Sci.* 2022, 23, 7907. [CrossRef]
57. R Studio Team. *RStudio: Integrated Development for R;* RStudio, PBC: Boston, MA, USA, 2020. Available online: [http://www.rstudio.com/](http://www.rstudio.com/) (accessed on 6 July 2022).
58. R Core Team. *R: A Language and Environment for Statistical Computing;* R Foundation for Statistical Computing: Vienna, Austria, 2021. Available online: [https://www.R-project.org/](https://www.R-project.org/) (accessed on 6 July 2022).